Redx in cancer research partnership
DRUG company Redx has announced a cancer research collaboration with international life science group Horizon Discovery Group.
It will focus on Liverpool and Alderley Park-based Redx’s existing pan-RAF inhibitor programme for colorectal cancer, the fourth most common cancer and the second most cause of death from the disease in the UK.
The pan-RAF inhibitor programme has identified next generation novel small molecule inhibitors of RAF kinases as potential treatments for colorectal and other potential cancers.
As part of the collaboration, Horizon will deploy its proprietary gene editing, cell line and drug discovery technology platforms and know how to help explore the mode of action of Redx’s pan-RAF inhibitors and support the company as it seeks to move towards licensing.
Under the terms of the agreement, Redx and Cambridge-based Horizon will bear costs proportionately to respective research activities and have agreed a revenue share for any successful out-licensing.
Redx chief executive Dr Neil Murray said: “Our pan-RAF inhibitor program is dealing with novel biology and is at a very interesting point. Our partnership with Horizon will enable us to detail at molecular level the effects of our pan-RAF inhibitors and help to progress this very promising program as we seek to secure a license partner for this asset.”
Horizon chief executive Dr Darrin M Disley added: “We are delighted to be able to support Redx with our proprietary technology platforms as they move towards securing a licensing agreement for these novel assets.”
